# idiopathic pulmonary fibrosis (IPF) - gemini-3.6-flash

- Benchmark system: raw
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 5217
- Completion tokens: 12341
- Reasoning tokens: 
- Total tokens: 17558
- API requests reported: 
- Elapsed seconds: 24.835
- Final benchmark system: raw; file rank 1/5; original repeat 2; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

This transcriptomic dataset evaluates the association between lung tissue gene expression and all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). 

The risk-associated features ($\text{HR} > 1$, $\text{FDR} < 0.05$) reveal five primary, interconnected biological processes driving disease progression and mortality:
1. **Aberrant Distal Epithelial Reprogramming and Mucociliary Dysregulation:** Upregulation of distal airway epithelial and basaloid markers (*KRT17*, *MUC1*, *MUC21*, *SFTPB*, *CEACAM6*, *S100A14*) reflects the loss of normal alveolar Type 1/Type 2 architecture and expansion of aberrant basaloid/bronchiolar epithelium.
2. **Profibrotic and Inflammatory Myeloid Cell Infiltration:** Strong upregulation of macrophage- and neutrophil-derived signals (*SPP1*, *MERTK*, *STAB1*, *S100A12*, *CCL7*, *CXCL1*, *CXCR1*) indicates persistent innate immune activation and accumulation of profibrotic monocyte-derived macrophages.
3. **Extracellular Matrix (ECM) Remodeling and Cytoskeletal Reorganization:** High expression of pericellular proteases, matrix components, and actin-binding regulators (*HTRA1*, *EFEMP1*, *CHST15*, *MARCKS*, *BASP1*, *FHL2*, *KANK1*) marks active matrix stiffening and myofibroblast migration.
4. **Receptor Tyrosine Kinase (RTK) and Growth Factor Signaling:** Co-elevation of growth factor pathways (*HGF*, *MET*, *NRG1*, *BMP6*, *SPRY2*) highlights altered wound-healing cascades and receptor cross-talk in damaged tissue microenvironments.
5. **Cellular Stress Adaptation and Metabolic Transporter Rewiring:** Upregulation of solute transporters and redox regulators (*SLC7A11*, *SLC6A8*, *SLC39A8*, *CYP4F3*, *SOD3*) reflects metabolic survival adaptations under chronic hypoxia and oxidative stress.

#### Technical Artifact Identification
The dataset contains several features exhibiting extreme hazard ratios ($\text{HR} \approx 5.18 \times 10^{21}$ or $\text{HR} \approx 1.93 \times 10^{-22}$) alongside nominal $P = 0$ and $\text{FDR} = 0$ (e.g., *MIR221*, *IHH*, *HCN4*, *CONTROL_A_33_P3222196*, *CONTROL_A_33_P3345409*, *DKFZP434L187*). These values are mathematical and computational artifacts resulting from numerical non-convergence, zero-variance distributions, or unannotated control probe signals in standard Cox proportional hazards algorithms. They are excluded from substantive biological interpretation.

---

### 2. Core Biological Programs

```
                       +-------------------------------------------------------+
                       |               IPF Lung Tissue Microenvironment        |
                       +-------------------------------------------------------+
                                                   |
         +------------------+----------------------+----------------------+------------------+
         |                  |                      |                      |                  |
         v                  v                      v                      v                  v
+------------------+ +------------------+ +------------------+ +------------------+ +------------------+
| Program 1:       | | Program 2:       | | Program 3:       | | Program 4:       | | Program 5:       |
| Dysplastic       | | Profibrotic      | | ECM              | | RTK / Growth     | | Stress Response |
| Epithelial       | | Myeloid          | | Reorganization & | | Factor           | | & Metabolic    |
| Reprogramming    | | Activation       | | Cytoskeleton     | | Signaling        | | Rewiring         |
| (KRT17, MUC1,    | | (SPP1, MERTK,    | | (HTRA1, EFEMP1,  | | (HGF, MET,       | | (SLC7A11,      |
| SFTPB)           | | S100A12)         | | MARCKS)          | | NRG1)            | | SOD3, CYP4F3)  |
+------------------+ +------------------+ +------------------+ +------------------+ +------------------+
         |                  |                      |                      |                  |
         +------------------+----------------------+----------------------+------------------+
                                                   |
                                                   v
                                 +-----------------------------------+
                                 | Progressive Fibrosis & Mortality  |
                                 +-----------------------------------+
```

#### Program 1: Dysplastic/Aberrant Epithelial Reprogramming & Airway Remodeling
* **Direction:** Risk-associated ($\text{HR} > 1$)
* **Major Supporting Genes:** *MUC1* ($\text{HR} = 2.32$), *KRT17* ($\text{HR} = 2.19$), *SFTPB* ($\text{HR} = 2.66$), *CEACAM6* ($\text{HR} = 2.66$), *S100A14* ($\text{HR} = 2.57$), *SFTA2* ($\text{HR} = 2.25$), *MUC21* ($\text{HR} = 2.10$), *PRSS8* ($\text{HR} = 2.57$), *AGR3* ($\text{HR} = 2.40$)
* **Standardized Pathway:** GO:0002064 (epithelial cell development) / Hallmark Epithelial-Mesenchymal Transition
* **Biological Rationale:** Fibrotic pulmonary remodeling in IPF involves honeycomb cyst formation and the expansion of $KRT17^+$ aberrant basaloid epithelial cells. Upregulation of mucins (*MUC1*, *MUC21*) alongside persistent surfactant transcript production (*SFTPB*, *SFTA2*) indicates failure of normal alveolar repair and transition toward a dysplastic epithelial phenotype.
* **Evidence & Limitations:** High strength; multiple independent epithelial markers show consistent direction. Limitation: Bulk transcriptomics cannot resolve whether signal elevation stems from higher per-cell expression or cellular expansion.

#### Program 2: Profibrotic & Inflammatory Myeloid / Macrophage Activation
* **Direction:** Risk-associated ($\text{HR} > 1$)
* **Major Supporting Genes:** *SPP1* ($\text{HR} = 3.40$), *MERTK* ($\text{HR} = 3.70$), *S100A12* ($\text{HR} = 2.53$), *STAB1* ($\text{HR} = 3.29$), *MMP25* ($\text{HR} = 3.26$), *CXCR1* ($\text{HR} = 3.28$), *CCL7* ($\text{HR} = 3.02$), *CXCL1* ($\text{HR} = 2.99$), *CD177* ($\text{HR} = 2.72$)
* **Standardized Pathway:** Reactome: R-HSA-6783783 (Interleukin-10 signaling) / KEGG: hsa04620 (Toll-like receptor signaling pathway)
* **Biological Rationale:** Osteopontin (*SPP1*) is a classic marker of pro-fibrotic alveolar macrophages in IPF. The concurrent elevation of phagocytic/efferocytic receptors (*MERTK*, *STAB1*) and neutrophil chemokines/activation markers (*S100A12*, *CXCL1*, *CCL7*, *CD177*) demonstrates that active myeloid recruitment and efferocytic clearance pathways are strongly linked to shorter survival.
* **Evidence & Limitations:** Supported by single-cell lung atlases. Limitation: Overlap exists between resident macrophage activation and circulating monocyte/neutrophil recruitment markers in bulk homogenates.

#### Program 3: Extracellular Matrix Reorganization & Pericellular Cytoskeletal Dynamics
* **Direction:** Risk-associated ($\text{HR} > 1$)
* **Major Supporting Genes:** *HTRA1* ($\text{HR} = 4.30$), *MARCKS* ($\text{HR} = 4.00$), *BASP1* ($\text{HR} = 3.77$), *EFEMP1* ($\text{HR} = 2.33$), *CHST15* ($\text{HR} = 2.99$), *FHL2* ($\text{HR} = 2.76$), *KANK1* ($\text{HR} = 3.59$), *ENAH* ($\text{HR} = 2.03$)
* **Standardized Pathway:** Reactome: R-HSA-1474244 (Extracellular matrix organization) / GO:0030198 (extracellular matrix organization)
* **Biological Rationale:** Active remodeling of the interstitial matrix is mediated by pericellular proteases like *HTRA1* (which processes matrix components and regulates TGF-$\beta$ bioavailability) and proteoglycan modifying enzymes like *CHST15*. Cytoskeletal regulators (*MARCKS*, *BASP1*, *FHL2*, *KANK1*) facilitate myofibroblast contractility and mechanotransduction.
* **Evidence & Limitations:** High statistical significance across independent structural components. Limitation: mRNA levels do not directly quantify enzymatic cleavage rates or tissue stiffness.

#### Program 4: Growth Factor & Receptor Tyrosine Kinase (RTK) Signaling Cascades
* **Direction:** Risk-associated ($\text{HR} > 1$)
* **Major Supporting Genes:** *HGF* ($\text{HR} = 2.93$), *MET* ($\text{HR} = 2.53$), *NRG1* ($\text{HR} = 2.76$), *SPRY2* ($\text{HR} = 3.26$), *BMP6* ($\text{HR} = 3.04$), *PROK2* ($\text{HR} = 3.65$)
* **Standardized Pathway:** Reactome: R-HSA-9006934 (Signaling by MET) / KEGG: hsa04014 (Ras signaling pathway)
* **Biological Rationale:** Parallel upregulation of Hepatocyte Growth Factor (*HGF*) and its receptor *MET*, combined with Neuregulin-1 (*NRG1*) and the RTK feedback inhibitor Sprouty 2 (*SPRY2*), indicates unresolvable growth factor signaling. Chronic RTK activation combined with induced negative feedback loops reflects persistent, aberrant tissue repair activity.
* **Evidence & Limitations:** Strong internal consistency due to matched ligand-receptor pairs (*HGF*-*MET*). Limitation: Protein phosphorylation state cannot be confirmed from transcript abundance.

#### Program 5: Cellular Stress Response & Transporter / Metabolic Rewiring
* **Direction:** Risk-associated ($\text{HR} > 1$)
* **Major Supporting Genes:** *SLC7A11* ($\text{HR} = 3.52$), *SLC6A8* ($\text{HR} = 3.21$), *SLC39A8* ($\text{HR} = 3.22$), *CYP4F3* ($\text{HR} = 3.78$), *ACOX2* ($\text{HR} = 3.18$), *SOD3* ($\text{HR} = 2.37$), *METTL7B* ($\text{HR} = 3.34$)
* **Standardized Pathway:** KEGG: hsa00480 (Glutathione metabolism) / Reactome: R-HSA-9711123 (Cellular responses to stimuli)
* **Biological Rationale:** Stressed epithelial and fibroblastic populations alter metabolic pathways to survive hostile, hypoxic tissue microenvironments. *SLC7A11* (xCT cystine/glutamate antiporter) protects cells from oxidative ferroptosis, while *SOD3* modifies extracellular redox state and *CYP4F3*/*ACOX2* drive altered lipid metabolism.
* **Evidence & Limitations:** Multiple solute carriers show concordant risk associations. Limitation: Functional metabolite turnover requires mass spectrometry validation.

---

### 3. Key Genes and Interaction Modules

| Gene / Module | Direction ($\text{HR}$, $\text{FDR}$) | Core Program Alignment | Proposed Interaction & Relationship Type |
| :--- | :--- | :--- | :--- |
| **SPP1** | Risk ($\text{HR} = 3.40$, $\text{FDR} = 3.99\times 10^{-5}$) | Profibrotic Myeloid Activation | **Co-expression & Receptor-Ligand:** Expressed by profibrotic macrophages; interacts with cell-surface integrins/CD44 on myofibroblasts (*Pathway co-membership / Receptor-ligand*). |
| **HGF – MET Module** | Risk (*HGF*: $\text{HR} = 2.93$, $\text{FDR} = 1.09\times 10^{-5}$; *MET*: $\text{HR} = 2.53$, $\text{FDR} = 1.47\times 10^{-5}$) | RTK / Growth Factor Signaling | **Direct Physical Interaction:** HGF protein directly binds the MET receptor tyrosine kinase (*Direct physical / Ligand-receptor interaction*). |
| **HTRA1** | Risk ($\text{HR} = 4.30$, $\text{FDR} = 2.57\times 10^{-6}$) | ECM Reorganization | **Regulatory & Proteolytic Interaction:** Cleaves extracellular matrix substrates and matrix-bound latent TGF-$\beta$ complexes (*Regulatory interaction*). |
| **KRT17 – MUC1 – SFTPB Module** | Risk (*KRT17*: $\text{HR} = 2.19$; *MUC1*: $\text{HR} = 2.32$; *SFTPB*: $\text{HR} = 2.66$) | Aberrant Epithelial Reprogramming | **Co-expression & Pathway Co-membership:** Shared expression within dysplastic airway epithelium and aberrant basaloid lineages (*Co-expression / Cell lineage co-membership*). |
| **SLC7A11** | Risk ($\text{HR} = 3.52$, $\text{FDR} = 1.09\times 10^{-5}$) | Stress Response & Transporter Rewiring | **Indirect Functional Relationship:** Mediates cystine uptake for glutathione biosynthesis, functionally intersecting with antioxidant networks like *SOD3* (*Pathway co-membership*). |
| **MARCKS – BASP1 Module** | Risk (*MARCKS*: $\text{HR} = 4.00$, $\text{FDR} = 2.12\times 10^{-5}$; *BASP1*: $\text{HR} = 3.77$, $\text{FDR} = 1.89\times 10^{-5}$) | Cytoskeletal Dynamics | **Co-expression & Functional Co-membership:** Both are PKC substrate proteins regulating membrane-actin interface dynamics (*Co-expression / Functional pathway co-membership*). |
| **MERTK – STAB1 Module** | Risk (*MERTK*: $\text{HR} = 3.70$, $\text{FDR} = 1.05\times 10^{-5}$; *STAB1*: $\text{HR} = 3.29$, $\text{FDR} = 3.15\times 10^{-5}$) | Profibrotic Myeloid Activation | **Co-expression:** Shared marker expression on phagocytic/efferocytic tissue-resident and recruited macrophage subsets (*Co-expression*). |
| **SPRY2 – NRG1 Axis** | Risk (*SPRY2*: $\text{HR} = 3.26$, $\text{FDR} = 1.69\times 10^{-5}$; *NRG1*: $\text{HR} = 2.76$, $\text{FDR} = 6.85\times 10^{-6}$) | RTK / Growth Factor Signaling | **Regulatory Interaction:** SPRY2 acts as an intracellular negative-feedback regulator of RTK signaling activated by growth factors including NRG1 and HGF (*Regulatory interaction*). |
| **Technical Artifact Group** (*MIR221*, *IHH*, *CONTROL_A_33...*) | Extreme Artifact ($\text{HR} \approx 10^{-22} / 10^{21}$, $\text{FDR} = 0$) | N/A (Methodological) | **None (Statistical Artifact):** No biological interaction; shared computational non-convergence/zero-variance artifact in regression models (*Statistical artifact*). |

---

### 4. Validation Priorities

#### Priority 1: SLC7A11-Mediated Ferroptosis Suppression in Fibrotic Stroma
* **Classification:** Mechanistic hypothesis
* **Prioritization Rationale:** *SLC7A11* displays a high risk hazard ratio ($\text{HR} = 3.52$). Targeting ferroptosis resistance in persistent myofibroblasts represents a novel therapeutic angle in pulmonary fibrosis.
* **Current Dataset Evidence:** Strong statistical signal ($\text{FDR} = 1.09 \times 10^{-5}$) linking *SLC7A11* to decreased overall survival.
* **External Evidence:** Published literature demonstrates that *SLC7A11* (xCT) is upregulated in TGF-$\beta1$-activated fibroblasts and protects stressed stromal cells from lipid peroxidation.
* **Next Validation Step:** Perform lipid ROS and ferroptosis induction assays (e.g., erastin/sulfasalazine treatment) in primary IPF patient-derived lung fibroblasts and 3D precision-cut lung slices (PCLS).
* **Current Evidence Status:** Supported hypothesis

#### Priority 2: Therapeutic Inhibition of HTRA1 Enzymatic Activity
* **Classification:** Therapeutic target
* **Prioritization Rationale:** *HTRA1* exhibits one of the highest functional risk hazard ratios ($\text{HR} = 4.30$, $\text{FDR} = 2.57 \times 10^{-6}$) among druggable pericellular enzymes.
* **Current Dataset Evidence:** Robust correlation with mortality across patient samples.
* **External Evidence:** HTRA1 is known to degrade matrix proteins and release active TGF-$\beta$ from latent membrane complexes.
* **Next Validation Step:** Evaluate small-molecule or neutralizing antibody inhibitors of HTRA1 in human PCLS and bleomycin-induced pulmonary fibrosis mouse models, monitoring collagen deposition and TGF-$\beta$ signaling flux.
* **Current Evidence Status:** Exploratory hypothesis

#### Priority 3: Dual SPP1 / KL-6 (MUC1) Plasma Biomarker Panel for Patient Stratification
* **Classification:** Biomarker
* **Prioritization Rationale:** Combining markers for profibrotic macrophages (*SPP1*, $\text{HR} = 3.40$) and aberrant epithelium (*MUC1*, $\text{HR} = 2.32$) captures multi-compartment pathology.
* **Current Dataset Evidence:** Both transcripts independently show strong adverse risk associations.
* **External Evidence:** Circulating SPP1 and KL-6 (shed MUC1 protein) are validated single biomarkers in clinical IPF cohorts (e.g., PROFILE study).
* **Next Validation Step:** Assess whether baseline combined ELISA measurements of SPP1 and KL-6 improve mortality predictive performance ($\text{C-index}$) over clinical metrics (FVC, DLCO) alone in an independent prospective cohort.
* **Current Evidence Status:** Supported hypothesis (individual markers are established; dual predictive utility is supported).

#### Priority 4: Spatial Mapping of the HGF–MET–SPRY2 Autocrine/Paracrine Loop
* **Classification:** Interaction / network hypothesis
* **Prioritization Rationale:** *HGF* ($\text{HR} = 2.93$), *MET* ($\text{HR} = 2.53$), and the RTK regulator *SPRY2* ($\text{HR} = 3.26$) are concurrently risk-associated, suggesting unresolvable growth factor signaling feedback loops.
* **Current Dataset Evidence:** Co-elevation of ligand, receptor, and negative feedback inhibitor transcripts.
* **External Evidence:** HGF/MET signaling promotes epithelial survival, but chronic signaling in dense fibrotic environments can drive persistent repair failure.
* **Next Validation Step:** Perform multiplexed single-molecule FISH or spatial transcriptomics on human IPF lung sections to resolve whether *HGF* and *MET* are expressed in adjacent stromal-epithelial microenvironments or co-expressed in aberrant basaloid cells.
* **Current Evidence Status:** Supported hypothesis

#### Priority 5: Single-Cell Deconvolution Check for Epithelial and Myeloid Composition Bias
* **Classification:** Confounding or composition check
* **Prioritization Rationale:** High hazard ratios for cell-type-specific lineage markers (*KRT17*, *SPP1*, *CD177*) may reflect tissue sampling composition (e.g., proportion of fibrotic scar vs. healthy alveoli) rather than per-cell gene induction.
* **Current Dataset Evidence:** Widespread elevation of diverse lineage-specific markers across epithelial, macrophage, and neutrophil compartments.
* **External Evidence:** Single-cell RNA-seq atlases confirm massive shifts in lung cell-type proportions during end-stage IPF.
* **Next Validation Step:** Apply CIBERSORTx or Scaden deconvolution to the bulk transcriptomic profiles using single-cell lung reference maps, re-running Cox proportional hazard models conditioned on estimated cell-type fractions.
* **Current Evidence Status:** Supported hypothesis

---

### 5. Evidence Grounding & Synthesis

```
+-----------------------------------------------------------------------------------------+
|                                    EVIDENCE MATRIX                                      |
+--------------------------+-----------------------+----------------------+---------------+
| Biological Process       | Direct Dataset Result | External Literature  | Interaction   |
|                          | (Statistical Hazard)  | Validation           | Nature        |
+--------------------------+-----------------------+----------------------+---------------+
| Profibrotic Macrophages  | SPP1 (HR=3.40)        | Single-cell atlases  | Cell-type     |
|                          | MERTK (HR=3.70)       | confirm macrophage   | co-expression |
|                          |                       | expansion in IPF     |               |
+--------------------------+-----------------------+----------------------+---------------+
| Dysplastic Epithelium    | KRT17 (HR=2.19)       | Aberrant basaloid    | Cell lineage  |
|                          | MUC1 (HR=2.32)        | cell expansion       | co-membership |
+--------------------------+-----------------------+----------------------+---------------+
| ECM / Proteolysis        | HTRA1 (HR=4.30)       | Matrix processing &  | Enzymatic /   |
|                          | EFEMP1 (HR=2.33)      | TGF-beta release     | Structural    |
+--------------------------+-----------------------+----------------------+---------------+
| RTK Signaling Loop       | HGF (HR=2.93)         | Epithelial repair    | Direct        |
|                          | MET (HR=2.53)         | signal dysfunction   | Ligand-Receptor|
+--------------------------+-----------------------+----------------------+---------------+
```

#### Multi-Source Evidence Integration
1. **Profibrotic Macrophage Axis (*SPP1*, *MERTK*):** Supported by direct dataset statistics ($\text{FDR} < 10^{-4}$) and external single-cell RNA-seq datasets (e.g., Kaminski/Lafyatis single-cell IPF atlases), which independently identify $SPP1^+/\text{MERTK}^+$ macrophages as expanded drivers of fibrosis. These represent genuinely independent evidence streams validating cell population expansion.
2. **Aberrant Basaloid Epithelial Axis (*KRT17*, *MUC1*):** Supported by direct statistical hazard associations and histological evidence in published literature confirming the presence of $KRT17^+$ basaloid cells in fibroblastic foci. However, direct transcriptomic signal strength in bulk samples is heavily collinear with regional tissue remodeling severity.
3. **Pericellular Matrix Degradation (*HTRA1*):** Supported by high hazard ratios in the input dataset ($\text{HR} = 4.30$) and biochemical studies demonstrating HTRA1-mediated cleavage of fibronectin and latent TGF-$\beta$-binding protein-1 (LTBP1).

#### Identification of Conflicting or Insufficient Evidence
* **HGF/MET Axis Dual Role:** In acute lung injury literature, HGF/MET signaling is frequently documented as protective and pro-regenerative. In the present IPF prognostic dataset, high expression of both *HGF* ($\text{HR} = 2.93$) and *MET* ($\text{HR} = 2.53$) is associated with *increased* mortality. This apparent conflict reflects context-dependent biology: in established, severe IPF, elevated HGF/MET signaling likely reflects persistent, unresolvable epithelial injury and dense stromal remodeling rather than successful repair.
* **Unannotated / LncRNA Loci:** Transcripts such as *LOC100128226* ($\text{HR} = 0.0070$, $\text{FDR} = 4.80 \times 10^{-35}$) and non-coding transcripts (*MRVI1-AS1*, *lincRNA:chr2:74193717...*) lack functional characterization in pulmonary pathology. They represent **insufficient evidence** for functional mechanistic conclusions prior to experimental targeted knockdown.

---

### 6. Limitations and Alternative Explanations

1. **Cell Composition and Tissue Heterogeneity Confounding:** Bulk lung tissue transcriptomics reflects a composite average of epithelial, endothelial, stromal, and immune cells. Elevated hazard ratios for lineage markers like *KRT17* (basaloid cells) or *SPP1* (macrophages) may simply reflect an increased volume of fibrotic scar tissue relative to normal parenchyma in the biopsy specimen, rather than active per-cell transcriptional induction.
2. **Numerical Regression Non-Convergence Artifacts:** Features exhibiting extreme hazard ratios ($\text{HR} \approx 10^{21}$ or $\text{HR} \approx 10^{-22}$) with nominal $P = 0$ (e.g., *MIR221*, *IHH*, *CONTROL_A_33_P3222196*) stem from perfect statistical separation or near-zero variance in patient subgroups within the Cox proportional hazards model. These features must not be interpreted as functional biological drivers.
3. **Biopsy Sampling and Disease Severity Bias:** Patients undergoing lung tissue sampling at advanced disease stages naturally exhibit higher baseline expression of injury and remodeling transcripts. If disease stage and physiological parameters (e.g., baseline Forced Vital Capacity) are not controlled for in the survival model, gene associations may reflect disease severity at time of sampling rather than true rates of disease progression.
4. **Treatment Exposure Confounding:** Patient exposure to antifibrotic therapy (pirfenidone, nintedanib) or historical immunosuppressive regimens (corticosteroids) substantially alters pulmonary transcript expression and patient survival. Lacking adjustment for concurrent treatment profiles introduces potential pharmacological confounding.
5. **Reverse Causality / Unsuccessful Compensatory Signaling:** Heightened expression of protective host response genes (e.g., the antioxidant enzyme *SOD3*, $\text{HR} = 2.37$, or the tissue repair factor *HGF*, $\text{HR} = 2.93$) may represent an unsuccessful, reactive upregulation triggered by severe oxidative stress and tissue damage. Interpreting these elevated risk transcripts strictly as harmful drivers of disease progression risks misinterpreting compensatory biology.
